Astra seeks EU okay for Seroquel XR in anxiety use
LONDON (Reuters) - AstraZeneca Plc is seeking European approval to sell its drug Seroquel XR as a treatment for anxiety, the Anglo-Swedish group said on Tuesday.
If approved, Seroquel XR would be the first atypical antipsychotic medicine cleared for the treatment of generalized anxiety disorder.
The European filing follows a similar U.S. submission in May and is part of a strategy to expand use of the medicine beyond schizophrenia.
Seroquel XR — a follow-on extended release version of AstraZeneca’s older $4 billion-a-year seller Seroquel — was approved for schizophrenia in 2007. It was also cleared in the United States as a treatment for bipolar disorder earlier this month.
WestLB analyst Simon Mather said the extended release version of the drug should partially offset sales lost when the immediate release formulation loses patent protection in 2011.
“Today’s news highlights the positive steps taken by the company to protect and further expand the franchise,” he said.
(Reporting by Ben Hirschler)
--------------------------------------------------------------------------------------------Related Posts:
By Susan Heavey WASHINGTON (Reuters) - Alpharma Inc’s powerful painkiller Embeda, which contains morphine sulfate and Duramorph, may not thwart drug abusers despite design features aimed at discouraging its misuse, U.S. regulatory staff said in documents released on Wednesday. The drugmaker tested the effects of the design features only when the pill was misused orally, but addicts
Full Post: FDA staff cite abuse concern with Embeda
--------------------------------------------------------------------------------------------
By Gene Emery BOSTON (Reuters) - Newer “atypical” drugs for schizophrenia and other mental problems, which are supposed to be safer, may in fact carry a greater risk of a fatal heart attack than older medicines, researchers said on Wednesday. The drugs are among the best-selling in the world and some experts suggested that the common practice
Full Post: Newer schizophrenia drugs cause heart risks: study
--------------------------------------------------------------------------------------------
By Julie Steenhuysen CHICAGO (Reuters) - The popular antidepressant Lexapro showed promise at easing anxiety symptoms in older adults, but the effect was “modest” and would need to be studied further, U.S. researchers said on Tuesday. They said antidepressants like Lexapro, made by Forest Laboratories Inc and known generically as escitalopram, may be useful as a new
Full Post: Lexapro may ease anxiety in older adults: study
--------------------------------------------------------------------------------------------
LONDON (Reuters) - European regulators on Thursday ruled against allowing a patent on developing human embryonic stem cells, a decision that could stifle research by stem cell companies for commercial purposes. An appeal panel at the European Patent Office upheld a June decision to reject a patent application regarding the use of stem cells filed by
Full Post: European agency rules against stem cell patents
--------------------------------------------------------------------------------------------
By Susan Heavey WASHINGTON (Reuters) - Data show Novartis AG’s combination malaria drug Coartem appears to work and causes few serious side effects, U.S. Food and Drug Administration regulatory staff said in documents released on Monday. “The majority of AEs (adverse events) were of mild or moderate intensity. Deaths … and SAEs (serious adverse events) … were
Full Post: Novartis malaria drug safe, effective: FDA